Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
eliglustat
|
| gptkbp:approvalYear |
2014
|
| gptkbp:ATCCode |
A16AB14
|
| gptkbp:CASNumber |
491833-29-5
|
| gptkbp:chemicalFormula |
C23H36N2O4
|
| gptkbp:contraindication |
severe hepatic impairment
CYP2D6 poor metabolizers with strong or moderate CYP3A inhibitors hypersensitivity to eliglustat |
| gptkbp:countryOfOperation |
gptkb:European_Union
gptkb:United_States |
| gptkbp:drugClass |
substrate reduction therapy
|
| gptkbp:form |
capsule
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cerdelga
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Sanofi_Genzyme
|
| gptkbp:mechanismOfAction |
glucosylceramide synthase inhibitor
|
| gptkbp:pregnancyCategory |
Not recommended
|
| gptkbp:prescriptionStatus |
Rx only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea abdominal pain constipation fatigue headache palpitations flatulence dyspepsia upper abdominal pain |
| gptkbp:usedFor |
gptkb:Gaucher_disease_type_1
|
| gptkbp:bfsParent |
gptkb:赛诺菲
|
| gptkbp:bfsLayer |
6
|